308
Participants
Start Date
October 2, 2014
Primary Completion Date
November 11, 2015
Study Completion Date
November 11, 2015
semaglutide
Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
semaglutide
Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
sitagliptin
Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido
Novo Nordisk Investigational Site, Chitose, Hokkaido
Novo Nordisk Investigational Site, Chuo-ku Tokyo
Novo Nordisk Investigational Site, Chuo-ku Tokyo
Novo Nordisk Investigational Site, Chuo-ku, Tokyo
Novo Nordisk Investigational Site, Ebina-shi
Novo Nordisk Investigational Site, Izumisano
Novo Nordisk Investigational Site, Kashiwara-shi, Osaka
Novo Nordisk Investigational Site, Katsushika-ku, Tokyo
Novo Nordisk Investigational Site, Kumamoto-shi,Kumamoto
Novo Nordisk Investigational Site, Naka-shi, Ibaraki
Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo
Novo Nordisk Investigational Site, Osaka-shi, Osaka
Novo Nordisk Investigational Site, Ota-ku, Tokyo
Novo Nordisk Investigational Site, Ota-ku, Tokyo
Novo Nordisk Investigational Site, Ōita
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi
Novo Nordisk Investigational Site, Shinjuku-ku, Tokyo
Novo Nordisk Investigational Site, Suita-shi, Osaka
Novo Nordisk Investigational Site, Takatsuki-shi, Osaka
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Yokohama
Novo Nordisk Investigational Site, Yokohama, Kanagawa
Lead Sponsor
Novo Nordisk A/S
INDUSTRY